Clinical Trial Update: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) [Phase 2]

View source ↗

Summary

The HERMIONE-7 Phase 2 trial evaluating abemaciclib in combination with aromatase inhibitors for HR+, HER2- advanced breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Aromatase inhibitor (Aromatase inhibitor)

Snippet

Sponsor: University of Milano Bicocca | Conditions: Advanced Breast Cancer | Phase 2 | Status: TERMINATED